Introduction
Smoking and high blood pressure have been identified as two major cardiovascular risk factors, accounting for a great proportion of total and cardiovascular mortality worldwide. Indeed, according to the latest estimations of the World Health Organization, more than 5 million deaths are attributable to the smoking habit and no less than 7 millions to high blood pressure (1) . The prevalence of smoking habit is estimated around 30% of adult population all over the world (47% in men and 12% in women) (2) and high blood pressure (≥ 140/90 mmHg) is found in no less than 30% of adult population in most countries, either developed or developing (3) . The coexistence of both risk factors in individuals at community level is aproximately 5%.
For decades it has been postulated that smokers shown lower blood pressure levels than non-smokers. Nevertheless, in recent years several epidemiological and clincal studies have demostrated the oposite, showing significant differences in 24-h blood pressure monitoring ( Figure 1 ) (4). Trends in prevalence of smoking and high blood pressure are relatively stable, with a slight increase related to the ageing process of the population in the case of high blood pressure and the little effect of the smoking prevention and control programmes, particularly on the youth. High blood pressure decisively increases the risk of cerebrovascular disease, coronary heart disease and renal failure, while smoking dramatically increases the risk of coronary heart disease, peripheral vascular disease and, in a less extent, cerebrovascular disease. The underlying mechanism in both cases is mainly the acceleration of atherosclerosis jointly with vascular and endothelial dysfunction. Nicotine, carbon monoxide, oxidants and cadmium are the main tobacco or tobacco smoke compounds that intervene in the physiopathological pathways leading to the organ damage. Some of them are connected with the physiological mechanisms of blood pressure regulation, which could explain the influence of smoking in blood pressure raising (Table 2 ) (6, 7)
In view of those evidences, smoking cessation is an essential component of the comprehensive management of hypertensive patients. Unfortunately, several studies have shown the limited involvement of physicians in antismoking initiatives, even in patients with smokingrelated chronic conditions (8) , and the maigre results of clinical interventions in terms of long-term smoking cessation in hypertensive population (9) . Therefore, more intensive efforts are needed to achieve better implication of physicians and other health professionals in smoking cessation at clinical level and in smoking prevention and control at community level (10 
Smoking cessation strategies in hypertensive patients
Smoking cessation strategies are currently very clearly defined after many years of worldwide experience. The available tools, either nonpharmacological or pharmacological, are deeply analysed in several qualified papers recently published (11) (12) (13) . They include counseling/minimal intervention, nicotine replacement, and bupropion as firstline therapies; additionally, one can use specialized phsychological intervention and other pharmacological agents (clonidine, antidepressants, etc.). These treatments should be implemented according to a stepped-based approach, like the one recommended many years ago for the treatment of hypertension (Table 3) , with the aim of facilitating the involvement of physicians in smoking cessation in clinical settings. Non-pharmacological strategies, namely counseling and minimal intervention (ask, advise, assess, assist, arrange) account for less than 5 minutes, so they can be regularly put into practice in every consultation of smoker patients. They are effective in approximately 15% on the average (14) . Concerning pharmacological treatment, the most widely used agents are nicotine replacement products (chewinggum, patch, nasal spray, inhaler and tablet) and bupropion. Depending on the context and on the intensity of the intervention, their effectiveness is estimated around 20-25% (14) . As a rule, the use of nicotine replacement in hypertensive patients does not need special caution, except in cases of severe and resistant hypertension and after a coronary event. In these cases nicotine replacement agents are contraindicated but, in general, they can be used following the same recommendations as for smokers as a whole. The only cautionary remark is avoiding their combination, which could supply a high dose of nicotine and, therefore, produce pressor effects (i.e. nicotine chewing-gum plus nicotine patch) (15) (16) (17) (18) .
Two final considerations are related to the harm reduction strategy and the frequent relapse. Concerning the later, during the following 12 months after the quit attempt around 70% of abstinents totally or partially relapse. This is similar to the situation in hypertension control (more than 60-70% of hypertensives under treatment remain with their blood pressure figures uncontrolled). Physicians have to be aware that the definitive abstinence from smoking very often comes only after several unsuccessful attempts. Consequently, they must insist over and over again in their efforts, helping their smoker patients to give up smoking (19) . In relation to the harm reduction strategy, it has been postulated in recent years with the aim of facilitating the integration of smoking cessation interventions in daily clinical practice, assuming that the reduction of risk is an optional objective when the complete abstinence is very difficult or even impossible (20) . Needless to say that the full abstinence, like the full hypertension control, remains as the main goal of the physicians' intervention. 
